Literature DB >> 19535526

Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients.

Patricia Sheen1, Melissa Méndez, Robert H Gilman, Lizeth Peña, Luz Caviedes, Mirko J Zimic, Ying Zhang, David A J Moore, Carlton A Evans.   

Abstract

Pyrazinamide is a first-line drug for treating tuberculosis, but pyrazinamide resistance testing is usually too slow to guide initial therapy, so some patients receive inappropriate therapy. We therefore aimed to optimize and evaluate a rapid molecular test for tuberculosis drug resistance to pyrazinamide. Tuberculosis PCR-single-strand conformational polymorphism (PCR-SSCP) was optimized to test for mutations causing pyrazinamide resistance directly from sputum samples and Mycobacterium tuberculosis isolates. The reliability of PCR-SSCP tests for sputum samples (n = 65) and Mycobacterium tuberculosis isolates (n = 185) from 147 patients was compared with four tests for pyrazinamide resistance: Bactec-460 automated culture, the Wayne biochemical test, DNA sequencing for pncA mutations, and traditional microbiological broth culture. PCR-SSCP provided interpretable results for 96% (46/48) of microscopy-positive sputum samples, 76% (13/17) of microscopy-negative sputum samples, and 100% of Mycobacterium tuberculosis isolates. There was 100% agreement between PCR-SSCP results from sputum samples and Mycobacterium tuberculosis isolates and 100% concordance between 50 blinded PCR-SSCP rereadings by three observers. PCR-SSCP agreement with the four other tests for pyrazinamide resistance varied from 89 to 97%. This was similar to how frequently the four other tests for pyrazinamide resistance agreed with each other: 90 to 94% for Bactec-460, 90 to 95% for Wayne, 92 to 95% for sequencing, and 91 to 95% for broth culture. PCR-SSCP took less than 24 hours and cost approximately $3 to $6, in contrast with the other assays, which took 3 to 14 weeks and cost $7 to $47. In conclusion, PCR-SSCP is a relatively reliable, rapid, and inexpensive test for pyrazinamide resistance that indicates which patients should receive pyrazinamide from the start of therapy, potentially preventing months of inappropriate treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19535526      PMCID: PMC2738130          DOI: 10.1128/JCM.01594-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  Handbook of anti-tuberculosis agents. Introduction.

Authors: 
Journal:  Tuberculosis (Edinb)       Date:  2008-03       Impact factor: 3.131

2.  Pyrazinamide resistance associated with pncA gene mutation in Mycobacterium tuberculosis in Japan.

Authors:  T Endoh; A Yagihashi; N Uehara; D Kobayashi; N Tsuji; M Nakamura; S Hayashi; N Fujii; N Watanabe
Journal:  Epidemiol Infect       Date:  2002-04       Impact factor: 2.451

Review 3.  The burden of drug-resistant tuberculosis and mechanisms for its control.

Authors:  M C Raviglione; R Gupta; C M Dye; M A Espinal
Journal:  Ann N Y Acad Sci       Date:  2001-12       Impact factor: 5.691

Review 4.  The curious characteristics of pyrazinamide: a review.

Authors:  Y Zhang; D Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2003-01       Impact factor: 2.373

5.  Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China.

Authors:  L Hou; D Osei-Hyiaman; Z Zhang; B Wang; A Yang; K Kano
Journal:  Epidemiol Infect       Date:  2000-04       Impact factor: 2.451

6.  [Studies on pncA gene mutations in M. tuberculosis isolates].

Authors:  X Wu; J Zhang; M Zhong
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2000-01

Review 7.  The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.

Authors:  Elizabeth L Corbett; Catherine J Watt; Neff Walker; Dermot Maher; Brian G Williams; Mario C Raviglione; Christopher Dye
Journal:  Arch Intern Med       Date:  2003-05-12

8.  Improved detection of Mycobacterium tuberculosis in Peruvian children by use of a heminested IS6110 polymerase chain reaction assay.

Authors:  Sonia H Montenegro; Robert H Gilman; Patricia Sheen; Rosa Cama; Lucy Caviedes; Terryl Hopper; Richard Chambers; Richard A Oberhelman
Journal:  Clin Infect Dis       Date:  2002-12-13       Impact factor: 9.079

9.  Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis.

Authors:  Srinivas V Ramaswamy; Robert Reich; Shu-Jun Dou; Linda Jasperse; Xi Pan; Audrey Wanger; Teresa Quitugua; Edward A Graviss
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

10.  pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea.

Authors:  S K Park; J Y Lee; C L Chang; M K Lee; H C Son; C M Kim; H J Jang; H K Park; S H Jeong
Journal:  BMC Infect Dis       Date:  2001-06-20       Impact factor: 3.090

View more
  16 in total

1.  Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance.

Authors:  Mirko Zimic; Patricia Fuentes; Robert H Gilman; Andrés H Gutiérrez; Daniela Kirwan; Patricia Sheen
Journal:  Tuberculosis (Edinb)       Date:  2011-10-17       Impact factor: 3.131

2.  Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China.

Authors:  Yaoju Tan; Zuqiong Hu; Tianyu Zhang; Xingshan Cai; Haobin Kuang; Yanwen Liu; Junyu Chen; Feng Yang; Ke Zhang; Shouyong Tan; Yanlin Zhao
Journal:  J Clin Microbiol       Date:  2013-10-16       Impact factor: 5.948

3.  Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China.

Authors:  Qiang Xia; Li-Li Zhao; Feng Li; Yu-Mei Fan; Yuan-Yuan Chen; Bei-Bei Wu; Zheng-Wei Liu; Ai-Zhen Pan; Min Zhu
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

4.  Mutation analysis of SLC26A4 for Pendred syndrome and nonsyndromic hearing loss by high-resolution melting.

Authors:  Neng Chen; Lisbeth Tranebjærg; Nanna Dahl Rendtorff; Iris Schrijver
Journal:  J Mol Diagn       Date:  2011-04-29       Impact factor: 5.568

Review 5.  Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses.

Authors:  Kwok Chiu Chang; Wing Wai Yew; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

6.  Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis.

Authors:  Karolien Stoffels; Vanessa Mathys; Maryse Fauville-Dufaux; René Wintjens; Pablo Bifani
Journal:  Antimicrob Agents Chemother       Date:  2012-07-23       Impact factor: 5.191

Review 7.  Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates.

Authors:  Sarah M Ramirez-Busby; Faramarz Valafar
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

8.  Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance.

Authors:  Mirko Zimic; Patricia Sheen; Miguel Quiliano; Andrés Gutierrez; Robert H Gilman
Journal:  Infect Genet Evol       Date:  2009-12-04       Impact factor: 3.342

9.  Rapid detection of Mycobacterium tuberculosis and pyrazinamide susceptibility related to pncA mutations in sputum specimens through an integrated gene-to-protein function approach.

Authors:  Heng Li; Jun Chen; Man Zhou; Xuelei Geng; Junping Yu; Weihua Wang; Xian-En Zhang; Hongping Wei
Journal:  J Clin Microbiol       Date:  2013-11-13       Impact factor: 5.948

10.  Mutational analysis of xenobiotic metabolizing genes (CYP1A1 and GSTP1) in sporadic head and neck cancer patients.

Authors:  Nosheen Masood; Mahmood Akhtar Kayani
Journal:  Genet Mol Biol       Date:  2011-10-01       Impact factor: 1.771

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.